Clavis, Clovis Shares Plunge on CO-101 Pancreatic Cancer Miss

Shares in Clavis Pharma ASA (OSLO:CLAVIS) plummeted by more than 87 percent Monday following the failure of CO-101 (CP-4126) to demonstrate any impact on survival in a pivotal Phase II trial in metastatic pancreatic cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)